Related Experiment Videos

The binding in vitro of modified LDL to the intermediate filament protein vimentin

A K Heidenthal1, P C Weber, F Lottspeich

  • 1Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Universität München, Pettenkoferstrasse 9, Münich, D-80336, Germany.

Insights

Vimentin, a cellular protein, binds modified low-density lipoprotein (LDL) but not native LDL. This specific binding suggests vimentin

Area of Science:

  • Cell Biology
  • Biochemistry
  • Atherosclerosis Research

Background:

  • Modified low-density lipoprotein (LDL) accumulation is central to atherosclerosis.
  • Cellular mechanisms of modified LDL uptake and retention are not fully understood.

Purpose of the Study:

  • To identify membrane-associated proteins that bind modified LDL in macrophages.
  • To elucidate the role of identified proteins in modified LDL processing.

Main Methods:

  • Ligand blotting of macrophage membrane proteins.
  • Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) for protein isolation.
  • Binding assays with purified vimentin and desmin using iodinated acetylated LDL ((125)I-AcLDL).
  • Site-directed mutagenesis of vimentin to identify binding domains.

Main Results:

  • A 54-kDa protein, identified as vimentin, specifically bound oxidized and acetylated LDL, but not native LDL.
  • Purified vimentin and desmin exhibited saturable binding of (125)I-AcLDL.
  • Amino acids 26-39 in vimentin's N-terminal head domain were essential for AcLDL binding.
  • Vimentin's cytoplasmic localization suggests a role in intracellular processing of modified LDL.

Conclusions:

  • Vimentin directly binds modified LDL in a specific and saturable manner.
  • Vimentin may contribute to the unregulated uptake and retention of oxidized LDL in atherogenic plaque cells.
  • Vimentin's interaction with modified LDL offers a potential target for understanding and treating atherosclerosis.

Related Concept Videos